Laura Huppert, MD

Articles

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

March 9th 2024

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

February 23rd 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer

February 16th 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

February 16th 2024

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

February 9th 2024

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

February 9th 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, provide an overview of the treatment landscape for HR+, HER2- advanced or metastatic breast cancer.

Dr Huppert on Sequential Treatment with T-DXd and Sacituzumab Govitecan in HER2-Low Breast Cancer

December 21st 2023

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

An Overview of HR+, HER2- Metastatic Breast Cancer

December 18th 2023

Experts provides an overview of HR-positive , HER2-negative metastatic breast cancer and current treatment approaches.